Latest Protease inhibitor Stories
BOSTON and RIDGEFIELD, Conn., Oct. 30, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
PITTSBURGH, Oct. 5 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S.
Nevirapine is widely used to help prevent mother-to-child transmission of the HIV virus. In cases where the infants are nonetheless infected with HIV virus at birth, the standard treatment is to use protease inhibitors (PI) to reduce the amount of virus in their bloodstream.
BRISBANE, Calif., Sept. 7 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at three upcoming healthcare conferences.
CAMBRIDGE, Mass., June 10 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc.
BRISBANE, Calif., May 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Steve Porter, M.D., Ph.D., Chief Medical Officer and Senior Vice President, Clinical Affairs of InterMune, will present at the 2010 Citi Health Care Conference in New York on May 26 at 3 p.m.
WALTHAM, Mass., March 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on available data and expert opinion, the telaprevir/peg-IFN-a-2a/ribavirin* regimen will earn Decision Resources proprietary clinical gold-standard status for the treatment of hepatitis C virus (treatment-naive population) in 2013, following telaprevir's approval for the indication in 2011. The...
ABBOTT PARK, Ill. and WATERTOWN, Mass., March 2 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Enanta Pharmaceuticals announced today the advancement of their Hepatitis C (HCV) collaboration into Phase 2 clinical trials.
BRISBANE, Calif., Jan. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13 at 4:00 p.m. PST.
BRISBANE, Calif., Dec. 11 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Steve Porter, M.D., Chief Medical Officer of InterMune, will present at the 2009 DB-Biotech Boston Confab on December 15, 2009 at 9:30 a.m. EST.
- An imitative word; an onomatopoetic word.